Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mesylate Apatinib for Stage Ⅳ Soft Tissue Sarcoma Patients After Failure of Traditional Chemotherapy: Prospective, Open-label, Single-Arm, Multi-center Phase II Clinical Trial

Next Previous
Trial Profile

Mesylate Apatinib for Stage Ⅳ Soft Tissue Sarcoma Patients After Failure of Traditional Chemotherapy: Prospective, Open-label, Single-Arm, Multi-center Phase II Clinical Trial

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivoceranib (Primary)
  • Indications Alveolar soft part sarcoma; Clear cell sarcoma; Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Nerve sheath neoplasms; Rhabdomyosarcoma; Soft tissue sarcoma; Synovial sarcoma
  • Focus Therapeutic Use

Most Recent Events

  • 04 Jun 2019 Results assessing chemotherapy combined with antiangiogenesis drugs in stage IV sarcoma patients using data from NCT03121833 and NCT03121846 studies, presented at the 55th Annual Meeting of the American Society of Clinical Oncology
  • 04 Jun 2019 Results (n=42) assessing efficacy and safety of Apatinib for patients with stage IV soft tissue sarcoma published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019)
  • 19 May 2017 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top